InvestorWire -- CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a clinical
stage biotechnology company specializing in the development of
novel treatments for primary and metastatic cancers of the brain
and central nervous system, today announces that it has been
featured in a broadcast via NetworkNewsAudio (“NNA”), a solution
that delivers additional visibility, recognition and brand
awareness in the investment community via distribution to thousands
of syndication points. The audio news release covers CNS
Pharmaceuticals’ recent announcement highlighting the activation of
its first clinical trial sites in Europe for the ongoing
potentially pivotal global trial evaluating Berubicin for the
treatment of recurrent glioblastoma multiforme (GBM), one of the
most aggressive types of brain cancer.
To hear the audio production, visit:
https://www.nnw.fm/TCHxT
To read the original press release, visit:
https://nnw.fm/js5dD
“Our primary focus continues to be on advancing the clinical
development of Berubicin as a potential treatment option for this
devastating disease. Over the course of this year, we have worked
diligently to expand patient eligibility for our potentially
pivotal trial and bolster our international presence now realized
with the activation of the first two European clinical trial
sites,” John Climaco, CEO of CNS Pharmaceuticals, stated in the
news release. “This is a true testament to our team's commitment to
and the execution of this important clinical program.”
Berubicin is a novel anthracycline and the first anthracycline
to appear to cross the blood-brain barrier. Berubicin is currently
being evaluated in a potentially pivotal global study evaluating
its efficacy and safety in the treatment of GBM. The potentially
pivotal trial is an adaptive, multicenter, open-label, randomized
and controlled study in adult patients with recurrent glioblastoma
multiforme (WHO Grade IV1) after failure of standard first-line
therapy. The primary endpoint of the study is Overall Survival
(OS), which is a rigorous endpoint that the FDA has recognized as a
basis for approval of oncology drugs when a statistically
significant improvement can be shown relative to a randomized
control arm. Results from the trial will compare Berubicin to a
current standard of care (Lomustine), with a 2 to 1 randomization
of patients to receive either Berubicin or Lomustine.
“We are grateful for the tremendous support from the clinical
staff and remain dedicated to driving patient enrollment as quickly
and efficiently as possible. We look forward to continuing to build
momentum and bringing Berubicin across the finish line to unlock
its greatest potential. As long as the unmet medical need in GBM
remains, we will continue our fight in earnest to bring hope to
patients and families globally,” Climaco added.
As detailed in the news release, the FDA has granted CNS
Pharmaceuticals Fast Track Designation for Berubicin, which enables
more frequent interactions with them to provide guidance on
expediting the development and review process. Additionally, the
company has also received Orphan Drug Designation from the FDA,
which may provide seven years of marketing exclusivity upon
approval of an NDA.
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals a clinical-stage pharmaceutical company
developing a pipeline of anti-cancer drug candidates for the
treatment of primary and metastatic cancers of the brain and
central nervous system. The company's lead drug candidate,
Berubicin, is a novel anthracycline and the first anthracycline to
appear to cross the blood-brain barrier. Berubicin is currently in
development for the treatment of a number of serious brain and CNS
oncology indications including glioblastoma multiforme (GBM), an
aggressive and incurable form of brain cancer.
Additionally, the company is advancing the development of its
WP1244 drug technology portfolio, which utilizes anthracycline and
distamycin-based scaffolds to create small molecule agents and is
believed to be 500x more potent than daunorubicin in inhibiting
tumor cell proliferation. Preclinical studies of WP1244
demonstrated high uptake in the brain with antitumor activity. CNS
Pharmaceuticals is evaluating the use of WP1244 in the treatment of
brain cancers, pancreatic, ovarian, and lymphomas.
For more information, please visit www.CNSPharma.com, and
connect with the company on Twitter, Facebook, and LinkedIn.
About NetworkNewsAudio
NetworkNewsAudio (“NNA”), one of 50+ brands within IBN
(InvestorBrandNetwork), allows you to sit back and listen to market
updates, CEO interviews and AudioPressRelease (“APR”) productions.
These audio clips provide snapshots of position, opportunity and
momentum. NNA can assist by cutting through the overload of
information in today's market, while bringing its clients
unparalleled visibility, recognition and brand awareness. IBN is
where news, content and information converge. IBN is a
comprehensive provider of news aggregation and syndication,
enhanced press release services and a full array of social
communication solutions. As a multifaceted financial news and
distribution company with an extensive team of journalists and
writers, IBN has the unparalleled ability to reach a wide audience
of investors, consumers, journalists and the general public with an
ever-growing distribution network of 5,000+ key syndication outlets
across the nation.
For more information, visit: www.NetworkNewsAudio.com
Please see full terms of use and disclaimers on the IBN website
applicable to all content provided by IBN, wherever published or
re-published: https://IBN.fm/Disclaimer
Forward-Looking Statements
Some of the statements in this press release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the timing of enrollment of
new patients and the ability of the Company to complete the trial
on a timely basis, if at all. These statements relate to future
events, future expectations, plans and prospects. Although CNS
believes the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may
prove to have been materially different from the results expressed
or implied by such forward-looking statements. CNS has attempted to
identify forward-looking statements by terminology including
''believes,'' ''estimates,'' ''anticipates,'' ''expects,''
''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,''
''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. These statements are
only predictions and involve known and unknown risks, uncertainties
and other factors, including those discussed under Item 1A. "Risk
Factors" in CNS's most recently filed Form 10-K filed with the
Securities and Exchange Commission ("SEC") and updated from time to
time in its Form 10-Q filings and in its other public filings with
the SEC. Any forward-looking statements contained in this press
release speak only as of its date. CNS undertakes no obligation to
update any forward-looking statements contained in this press
release to reflect events or circumstances occurring after its date
or to reflect the occurrence of unanticipated events.
Corporate Communications
IBN (InvestorBrandNetwork)Los Angeles,
Californiawww.InvestorBrandNetwork.com310.299.1717
OfficeEditor@InvestorBrandNetwork.com
CNS Pharmaceuticals (NASDAQ:CNSP)
Historical Stock Chart
From Jun 2024 to Jul 2024
CNS Pharmaceuticals (NASDAQ:CNSP)
Historical Stock Chart
From Jul 2023 to Jul 2024